Abstract 45P
Background
Pathologic complete response (pCR) is often utilized as a surrogate marker for overall survival in breast cancer. Significant differences in pCR rates are reported in many studies depending on the biological tumor profile and molecular classification. Based on our observations we hypothesize that few breast cancer patients are less likely to achieve pCR after neoadjuvant chemotherapy (NACT). The role of demographic variables in predicting pCR is still not clear. The aim of this study was to evaluate various demographic factors which could impact pCR rates.
Methods
A prospective analysis of 1246 patients with breast carcinoma who had undergone neoadjuvant chemotherapy (NACT) followed by surgery was done from June 2020 to December 2022. Demographic, surgical, and pathological data were collected on completion of therapy. Categorical variables were analyzed using χ2 or Fisher’s exact test and continuous data were analyzed using t-tests. Multiple linear regressions were used to study interactions between various demographic factors and pCR. Statistical analysis was done using SPSS v25.
Results
A total of 1324 patients were offered NACT, of which 1246 (94.1%) who underwent resection post-NACT were included in the analysis. Overall, 275 (22.1%) patients had pCR. 39 (14.2%) in ER+/HER2- group, 131 (47.6%) in HER2+ group; and 105 (38.2%) in ER-/HER2- group had pCR. Univariate analysis showed significant association between age <50 years, low body-mass index, and ability to achieve pCR. However, women with obesity had higher odds of residual disease (OR = 0.191 [0.029-1.157]; p=0.076). The results were consistent even after controlling for confounding variables such as grade, receptor status, and clinical T and N stages.
Conclusions
Younger age can predict a pCR and is an independent prognostic factor for locoregional recurrence in locally advanced breast cancer patients after NACT. Obesity is a risk factor for failure to achieve PCR in women undergoing NACT. The contrary was observed in non-obese patients as they had higher odds of achieving PCR. Studies with larger groups are needed to validate this observation. Further studies evaluating the role of BMI in drug resistance would be valuable.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
529P - Ramucirumab plus docetaxel after combination chemoimmunotherapy in patients with non-small cell lung cancer: A prospective observational study
Presenter: Tadaaki Yamada
Session: Poster Display
Resources:
Abstract
530P - MYC recruits tumor-associated macrophage to sustain metastatic malignancy of lung adenocarcinoma micropapillary subtype through epigenetic reprogramming
Presenter: Xuming Song
Session: Poster Display
Resources:
Abstract
531P - Effect of combinational targeted therapy for AXL and ATR against malignant mesothelioma cells
Presenter: Soichi Hirai
Session: Poster Display
Resources:
Abstract
532P - The changes of the serum SMRP levels is useful to predict the antitumor efficacy of ipilimumab plus nivolumab combination therapy in patients with malignant pleural mesothelioma
Presenter: Taiichiro Otsuki
Session: Poster Display
Resources:
Abstract
533P - Efficacy in the elderly NSCLC patients in SCORPION study: Phase II study of DTX plus RAM following platinum-based chemotherapy plus ICIs
Presenter: Teppei Yamaguchi
Session: Poster Display
Resources:
Abstract
534P - DSC2 promotes the proliferation, metastasis and drug resistance of lung cancer by activating the PI3K/AKT pathway
Presenter: Qi Li
Session: Poster Display
Resources:
Abstract
535P - Alteration in NKX2-1 CN reshapes the oncogenic, immunologic, and prognostic landscapes in NSCLC
Presenter: Herdee Gloriane Luna
Session: Poster Display
Resources:
Abstract
536P - The evaluation and long-term outcome of pulmonary metastasectomy for osteosarcoma: A 20-year experience of Shanghai Rujin Hospital
Presenter: Zhusheng Zhang
Session: Poster Display
Resources:
Abstract
537P - The impact of treatment-free interval on patient outcome after pulmonary metastasectomy for sarcoma
Presenter: Po-Kuei Hsu
Session: Poster Display
Resources:
Abstract
538P - First-line chemoimmunotherapy for metastatic thymic carcinoma
Presenter: Victoria Andreas
Session: Poster Display
Resources:
Abstract